Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses
Código 300120 (Harmonized System 2012 by 6 digits)
2024: US$1.64M, Total Trade Exchange
2024: US$499k, International Sales
2024: US$1.14M, International Purchases
Código 300120 (Harmonized System 2012 by 6 digits)
2024: US$1.64M, Total Trade Exchange
2024: US$499k, International Sales
2024: US$1.14M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses was US$1.64M.
In 2024, the states with the most international sales in Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were Ciudad de México (US$45k) and Estado de México (US$1.06k).
The states with the most international purchases in 2024 were Baja California (US$657k) and Ciudad de México (US$57.1k).
In 2024, the main commercial destinations of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were United States (US$40.1k), Panama (US$5.59k), Spain (US$312), Netherlands (US$49), and Ireland (US$12).
The main commercial origins of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses in 2024 were United States (US$657k), New Zealand (US$55.5k), United Kingdom (US$814), and Ukraine (US$223).
In the global context, the main exporting countries of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses in 2022 were United States (US$59.5M), China (US$35.3M), and Denmark (US$28.9M). In the same year, the main importing countries of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were Germany (US$66.3M), Italy (US$30.7M), and United States (US$28.3M).
US$1.64M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses in Mexico (including international purchases and sales) was US$1.64M.
The visualizations show the net balance of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025
In March 2025, international sales of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were US$69k, while international purchases reached US$94.1k. The above results in a trade balance of -US$25.1k.
2025-Q1: US$11.8k, International Sales
The visualization shows the quarterly concentration of international sales of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses at state level.
In the first quarter of 2025, international sales were US$11.8k, being the states with the most sales Ciudad de México (US$11.7k) and Estado de México (US$136).
Ciudad de México: US$45k, State with the Most International Sales (2024)
United States: US$40.1k, Main commercial destination (2024)
In 2024, the states with the highest international sales in Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were Ciudad de México (US$45k) and Estado de México (US$1.06k).
In 2024, the countries with the most international purchases from Mexico were United States (US$40.1k), Panama (US$5.59k), Spain (US$312), Netherlands (US$49), and Ireland (US$12).
Baja California: US$657k, State with the Most International Purchases (2024)
United States: US$657k, Main Commercial Origin (2024)
In 2024, the states with the highest international in Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were Baja California (US$657k) and Ciudad de México (US$57.1k).
The countries with the most international sales to Mexico in 2024 were United States (US$657k), New Zealand (US$55.5k), United Kingdom (US$814), and Ukraine (US$223).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were United States (US$59.5M), China (US$35.3M), and Denmark (US$28.9M). In the same year, the main importing countries for Extracts of Glands or other Organs or of their Secretions for Organo-Therapeutic Uses were Germany (US$66.3M), Italy (US$30.7M), and United States (US$28.3M).